Rigel Pharmaceuticals Inc
RIGLHealthcare|Biotechnology|USA
$42.55
-1.22 (-2.79%)
DCF (FCF)
$12.26
Tangible Book
$20.33
Graham Number
$92.54
Clinical Trials (43)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07486713 Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | AML (Acute Myeloid Leukemia), Glioma | P4 | Recruiting | 16 | Open-label | Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates |
| NCT06445959 Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib | Mutant IDH1 Inhibitor Olutasidenib | P1P2 | Recruiting | 78 | Open-label | Olutasidenib, Venetoclax, Decitabine, Decitabine/cedazuridine |
| NCT07471841 Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax | IDH1 Mutation, Relapsed / Refractory AML | P2 | Recruiting | 25 | Open-label | Olutasidenib, Azacitidine (AZA) |
| NCT05308264 Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Low Risk Myelodysplastic Syndromes | P1P2 | Recruiting | 86 | Open-label | R906289 Monosodium (R289 Na) |
| NCT07032727 Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations | Targeted Therapy, IDH1-Mutated Malignancies | P2 | Recruiting | 68 | Open-label | Olutasidenib, Cladribine (CLAD), Venetoclax, Gilteritinib, Ruxolitinib, Cytarabine |
| NCT06782542 Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy | Acute Myeloid Leukemia, IDH1 Mutation | P2 | Recruiting | 16 | Open-label | Olutasidenib, Venetoclax, Azacitidine |
| NCT06161974 Study of Olutasidenib and Temozolomide in HGG | High Grade Glioma, Astrocytoma | P2 | Recruiting | 60 | Open-label | Olutasidenib + TMZ |
| NCT06566742 A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. | Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | P2 | Recruiting | 15 | Open-label | Olutasidenib |
| NCT06233110 Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD | Chronic Graft Versus Host Disease | P1 | Recruiting | 30 | Single-blind | Fostamatinib, Ruxolitinib |
| NCT07130695 Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation | Acute Myeloid Leukemia | P1 | Recruiting | 15 | Open-label | Olutasidenib Investigational Agent Administration |
| NCT06639724 Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma (PDAC) | P1 | Recruiting | 36 | Open-label | — |
| NCT00774787 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses | Actinic Keratoses | P4 | Completed | 27 | RCT, Single-blind | imiquimod 5% cream |
| NCT02076399 A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) | Immune Thrombocytopenic Purpura | P3 | Completed | 76 | RCT, Double-blind | Fostamatinib disodium, Placebo |
| NCT04629703 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects | Covid19, SARS (Severe Acute Respiratory Syndrome) | P3 | Completed | 280 | RCT, Double-blind | Fostamatinib, Placebo |
| NCT04138927 A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | Warm Antibody Autoimmune Hemolytic Anemia | P3 | By Invite | 90 | Open-label | Fostamatinib disodium |
| NCT02077192 Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) | Immune Thrombocytopenic Purpura | P3 | Completed | 123 | Open-label | Fostamatinib Disodium |
| NCT03764618 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA | Warm Antibody Autoimmune Hemolytic Anemia | P3 | Completed | 90 | RCT, Double-blind | Fostamatinib disodium, Placebo |
| NCT02076412 A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) | Immune Thrombocytopenic Purpura | P3 | Completed | 74 | RCT, Double-blind | Fostamatinib Disodium, Placebo |
| NCT00446095 Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma | Lymphoma | P1P2 | Completed | 81 | Open-label | fostamatinib |
| NCT00326339 Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1) | Rheumatoid Arthritis | P2 | Completed | 189 | RCT, Double-blind | R788, Placebo |
| NCT05040698 Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa | Hidradenitis Suppurativa | P2 | Completed | 20 | Open-label | Fostamatinib |
| NCT00752999 Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | P2 | Withdrawn | — | RCT, Double-blind | Fostamatinib Disodium (R935788), Placebo |
| NCT02612558 A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) | Warm Antibody Autoimmune Hemolytic Anemia | P2 | Completed | 26 | Open-label | Fostamatinib 150 mg bid |
| NCT01900249 To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca | Keratoconjunctivitis Sicca | P2 | Completed | 204 | RCT, Double-blind | R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo |
| NCT00115089 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis | Rhinitis, Allergic, Seasonal | P2 | Completed | 375 | RCT, Double-blind | R926112, Beclomethasone dipropionate |
| NCT00665626 Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3) | Rheumatoid Arthritis | P2 | Completed | 219 | RCT, Double-blind | Fostamatinib disodium (R935788), Placebo |
| NCT01591044 A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma | Asthma | P2 | Completed | 301 | RCT, Double-blind | Placebo, R940343 1mg, R940343 2mg |
| NCT05848258 An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Completed | 164 | RCT, Double-blind | LY3871801, Placebo |
| NCT02040623 Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) | Chronic Graft-versus-host Disease | P2 | Completed | 35 | RCT, Double-blind | R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5% |
| NCT06597734 A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm | Chronic Myelomonocytic Leukemia, Advanced Myeloproliferative Neoplasms | P2 | Withdrawn | — | Open-label | Olutasidenib |
| NCT01597050 Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions | Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic | P2 | Completed | 54 | RCT, Double-blind | R932333, Placebo |
| NCT06564207 Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults | Acute Respiratory Distress Syndrome, ARDS | P2 | Not Yet Recruiting | 40 | RCT, Double-blind | Placebo, Fostamatinib |
| NCT00665925 Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Completed | 457 | RCT, Double-blind | Fostamatinib disodium (R935788), Fostamatinib disodium (R935788), Placebo |
| NCT02112838 Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy | IGA Nephropathy | P2 | Completed | 76 | RCT, Double-blind | Fostamatinib 150 mg, Fostamatinib 100 mg, Placebo |
| NCT02433236 Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy | IGA Nephropathy | P2 | Withdrawn | — | Open-label | Fostamatinib Disodium tablet 100 mg, Fostamatinib Disodium tablet 150 mg |
| NCT00706342 Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) | Purpura, Thrombocytopenic, Idiopathic | P2 | Completed | 18 | Open-label | Fostamatinib Disodium / R935788 |
| NCT04543279 Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia | Myelofibrosis, Thrombocytopenia | P2 | Terminated | 3 | Open-label | Fostamatinib, Ruxolitinib |
| NCT04581954 Inflammatory Signal Inhibitors for COVID-19 (MATIS) | Coronavirus, Covid19 | P1P2 | Completed | 185 | RCT, Single-blind | Ruxolitinib, Fostamatinib |
| NCT00798096 Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma | T Cell Lymphoma | P2 | Completed | 18 | Open-label | Fostamatinib Disodium |
| NCT03246074 Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | Ovarian Cancer | P1 | Completed | 35 | Open-label | Fostamatinib 100 mg bid and Paclitaxel, Fostamatinib 150 mg bid and Paclitaxel, Fostamatinib 200 mg bid and Paclitaxel |
| NCT01733992 A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease | Keratoconjunctivitis Sicca | P1 | Completed | 36 | RCT, Double-blind | R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, R348 Ophthalmic Solution, 1.0%, Placebo |
| NCT04904276 Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy | ITP, Immune Thrombocytopenia | Terminated | 16 | — | Fostamatinib | |
| NCT03363334 Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP | Immune Thrombocytopenic Purpura | NO_LONGER_AVAILABLE | — | — | Fostamatinib disodium 100 mg, Fostamatinib disodium 150 mg |